Immunotherapy with chemoradiation before surgery for thymic cancer
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding an immunotherapy drug called adebrelimab to chemotherapy and radiation before surgery can help shrink thymic cancer and improve outcomes. It is for people with locally advanced thymic carcinoma that can potentially be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with thymic carcinoma (a type of cancer in the thymus gland).
- Your cancer is locally advanced (stage T3 or T4) and has not spread to distant organs, and it can potentially be removed by surgery.
- You have not had any previous treatment for thymic cancer, such as surgery, radiation, chemotherapy, or immunotherapy.
- You are generally in good health, able to care for yourself (ECOG score 0-1), and have adequate organ function (heart, liver, kidneys, blood).
- You are willing to use effective contraception during the study and for 6 months after the last dose if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether additional chemotherapy after surgery can help prevent thymic cancer from coming back. It is for people who have had their thymus tumor completely removed and are in good health.
This trial tests a new treatment given before surgery for people with advanced thymic carcinoma. It aims to shrink the tumor and make surgery more effective.
This study tests a combination of two drugs (tislelizumab and anlotinib) as a second treatment option for people with thymoma or thymic carcinoma whose cancer has worsened after first-line therapy. It aims to see if this combination can control the tumor and improve outcomes.
This trial tests giving radiation therapy before surgery for a type of thymus gland tumor (thymoma) that has grown into nearby tissues but has not been treated yet. The goal is to see if this approach can make the tumor removable and improve outcomes.
This trial tests a new type of radiation (carbon ion) plus chemotherapy for thymic tumors that cannot be removed with surgery. It aims to see if this combination can effectively treat the cancer while protecting healthy organs.
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
Hear when a new Thymic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.